Articles published in Clinical Infectious Diseases: Open Access have been cited by esteemed scholars and scientists all around the world.
Clinical Infectious Diseases: Open Access has got h-index 3, which means every article in Clinical Infectious Diseases: Open Access has got 3 average citations.
Following are the list of articles that have cited the articles published in Clinical Infectious Diseases: Open Access.
| 2021 | 2020 | 2019 | |
|---|---|---|---|
Year wise published articles |
29 | 23 | 5 |
Year wise citations received |
4 | 4 | 1 |
| Journal total citations count | 49 |
| Journal 5 years impact factor | 0.14 |
| Journal cite score | 0.14 |
| Journal h-index | 3 |
| Journal h-index since 2018 | 2 |
Al-Baqer, Thaer M., Samar Abdul Raheem Al-Gharrawi, and Noor AL Huda A. Saeed. "Causative Microorganisms and Antibiotics Susceptibilities in Children with Urinary Tract Infection." Al-Mustansiriyah Journal of Science 32, no. 1 (2021): 5-9. |
|
Idrissa, H., O. Abdoulaye, A. Yacouba, D. Alhousseini Maiga, H. Moumouni Sambo, M. Doutchi, S. Chaibou, O. Sani, S. Mamadou, and L. Sangare. "Evaluation of the antimicrobial susceptibility testing process in clinical microbiology laboratories at Niamey, Niger." African Journal of Clinical and Experimental Microbiology 22, no. 4 (2021): 448-456. |
|
Dutta, Kunal, Amit Karmakar, Debarati Jana, Saroj Ballav, Sergey Shityakov, Amiya Kumar Panda, and Chandradipa Ghosh. "Benzyl isocyanate isolated from the leaves of Psidium guajava inhibits Staphylococcus aureus biofilm formation." Biofouling 36, no. 8 (2020): 1000-1017. |
|
Hameed, Wisam F., Yassien H. Owaid, Bashar S. Noomi, and Aswad H. Nada. "Silver and Cobalt nanoparticles as potential antibacterial agents Staphylococcus aureus isolated from wound infections." Tikrit Journal of Pure Science 25, no. 2 (2020): 21-24. |
|
El Shahaway, A. A., A. A. Ahmed, M. A. Arafa, and M. M. Malek. "Influence of HLA-G polymorphism in antibody response to hepatitis B vaccination during the first year of life." Vacunas (English Edition) 21, no. 2 (2020): 76-81. |
|
VERJEE, M. "Leprosy: A Time for Elimination by 2020." Clinical Infectious Diseases 2 (2018): 2. |
|
VERJEE, M. "Leprosy: A Time for Elimination by 2020." Clinical Infectious Diseases 2 (2018): 2. |
|
VERJEE, M. "Leprosy: A Time for Elimination by 2020." Clinical Infectious Diseases 2 (2018): 2. |
|
Odigie, Efosa Bolaji, and Micheal Awol Okungbowa. "Life style as a risk factor of human Papillomavirus co-infections with Trichomonas vaginalis in female sex workers." Universa Medicina 38, no. 1 (2019): 17-24. |
|
de Souza, Iaralice Medeiros, Milton Neto da Silva, Renata Chagas Bastos, Denise da Silva Gomes Pereira, Elza Cristina Schott Figueira, Ellen Jessouroun, Maria de Lourdes Moura Leal, Eliana Barreto-Bergter, and Ivna Alana Freitas Brasileiro da Silveira. "Development and Immunogenicity of a Brazilian Glycoconjugate vaccine against Meningococcal W in a Pilot Scale." Glycoconjugate Journal 38, no. 5 (2021): 539-549. |
|
Pietri, Gian Pietro, Marta Tontini, Barbara Brogioni, Davide Oldrini, Stefania Robakiewicz, Pedro Henriques, Ilaria Calloni et al. "Elucidating structural and minimal protective epitope of serogroup X meningococcal capsular polysaccharide." Frontiers in Molecular Biosciences (2021): 895. |
|
Pandiella, Atanasio, Eduardo Sanz, and Elena Díaz?Rodríguez. "Ocoxin oral solution demonstrates antiviral properties in cellular models." Experimental and therapeutic medicine 22, no. 4 (2021): 1-7. |
|
Posteraro, Brunella, Federico Pea, Luca Masucci, Patrizia Posteraro, and Maurizio Sanguinetti. "Actoxumab+ bezlotoxumab combination: what promise for Clostridium difficile treatment?." Expert opinion on biological therapy 18, no. 4 (2018): 469-476. |
|
Dinh, Aurélien, Alban Le Monnier, Corinne Emery, Sarah Alami, Élodie Torreton, Anne Duburcq, and François Barbier. "Predictors and burden of hospital readmission with recurrent Clostridioides difficile infection: a French nation-wide inception cohort study." European Journal of Clinical Microbiology & Infectious Diseases 38, no. 7 (2019): 1297-1305. |
|
Salavert, Miguel, Javier Cobo, Álvaro Pascual, Belén Aragón, Stefano Maratia, Yiling Jiang, Susana Aceituno, and Santiago Grau. "Cost-effectiveness analysis of bezlotoxumab added to standard of care versus standard of care alone for the prevention of recurrent Clostridium difficile infection in high-risk patients in Spain." Advances in therapy 35, no. 11 (2018): 1920-1934. |
|
Mejia-Chew, Carlos, and Erik R. Dubberke. "Clostridium difficile control measures: current and future methods for prevention." Expert review of anti-infective therapy 16, no. 2 (2018): 121-131. |
|
Vargas, Edwin, Senu Apewokin, and Rajat Madan. "Role of the leukocyte response in normal and immunocompromised host after Clostridium difficile infection." Anaerobe 45 (2017): 101-105. |
|
Kelly, Ciarán P., Ian R. Poxton, Judong Shen, Mark H. Wilcox, Dale N. Gerding, Xuemei Zhao, Omar F. Laterza, Radha Railkar, Dalya Guris, and Mary Beth Dorr. "Effect of endogenous Clostridioides difficile toxin antibodies on recurrence of C. difficile infection." Clinical Infectious Diseases 71, no. 1 (2020): 81-86. |
|
Mullane, Kathleen M., Erik R. Dubberke, and AST ID Community of Practice. "Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice." Clinical transplantation 33, no. 9 (2019): e13564. |
|
Hernández, Luis Alcalá, Elena Reigadas Ramírez, and Emilio Bouza Santiago. "Clostridium difficile infection." Medicina Clínica (English Edition) 148, no. 10 (2017): 456-463. |
|
Clinical Infectious Diseases: Open Access received 49 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 